ArticleCancers2026

Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety.

Hironao Okubo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.